P ZIDE Tablet
Pyrazinamide
750mg
Cadila Pharmaceuticals Limited.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 10.81 NPR |
Available as:
Indications
P ZIDE Tablet is used for:
Tuberculosis
Adult Dose
Oral
Tuberculosis
Adult: As part of a multidrug regimen: For standard unsupervised 2-mth treatment: <50 kg: 1.5 g daily; >50 kg: 2 g daily.
For intermittent supervised 2-mth treatment: <50 kg: 2 g 3 times wkly; >50 kg: 2.5 g 3 times wkly.
Hepatic impairment: Severe: Contraindicated.
Child Dose
Oral
Tuberculosis
Child: As part of a multidrug regimen: For standard unsupervised 2-mth treatment: 35 mg/kg daily.
For intermittent supervised 2-mth treatment: 50 mg/kg 3 times wkly.
Renal Dose
Renal impairment: May need dose reduction.
Administration
Should be taken with food.
Contra Indications
Hypersensitivity; existing liver disease; acute gout or hyperuricaemia. Porphyria. Pregnancy and lactation.
Precautions
Patient w/ DM, history of gout. Mild to moderate hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor liver function, serum uric acid, sputum culture; chest x-ray 2-3 mth into treatment and at completion.
Pregnancy-Lactation
Interactions
Antagonises the effect of uricosuric agents (e.g. probenecid, sulfinpyrazone). May reduce the contraceptive effect of oestrogens. May inactivate oral typhoid vaccine. May increase the serum concentration of ciclosporin. May enhance the hepatotoxic effect of rifampicin.
Adverse Effects
Side effects of Pyrazinamide :
1-10%
Malaise,Nausea,Vomiting,Anorexia,Arthralgia,Myalgia
<1%
Fever,Rash,Itching,Acne,Photosensitivity,Gout,Dysuria,Porphyria,Thrombocytopenia,Hepatotoxicity,Interstitial nephritis
Potentially Fatal: Severe liver damage, fulminant hepatitis.
Mechanism of Action
Pyrazinamide may be bacteriostatic or bactericidal in action, depending on the concentration of the drug attained at the site of the infection and the susceptibility of the infecting organism. Its activity appears to partly depend on conversion of the drug to pyrazinoic acid (POA), which lowers the pH of the environment below that which is necessary for growth of Mycobacterium tuberculosis. Susceptible strains of M. tuberculosis produce pyrazinamidase, an enzyme that deaminates pyrazinamide to POA, and the in vitro susceptibility of a given strain of the organism appears to correspond to its pyrazinamidase activity.
Note
P ZIDE 750mg Tablet manufactured by Cadila Pharmaceuticals Limited.. Its generic name is Pyrazinamide. P ZIDE is availble in Nepal.
Farmaco Nepal drug index information on P ZIDE Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.